These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26200175)

  • 1. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.
    Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH
    JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175
    [No Abstract]   [Full Text] [Related]  

  • 2. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
    Wolfe CM; Green WH; Cognetta AB; Hatfield HK
    Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
    [No Abstract]   [Full Text] [Related]  

  • 3. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
    Kieny A; Kremer V; Scheidecker S; Lipsker D
    Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
    Yang X; Dinehart SM
    JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
    [No Abstract]   [Full Text] [Related]  

  • 5. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
    Kutiel TS; Vornicova O; Bar-Sela G
    J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
    Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
    N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic changes in basal cell carcinoma after treatment with vismodegib.
    Aldabagh B; Yu J; Perkocha LA; Arron S
    Dermatol Surg; 2013 Nov; 39(11):1703-5. PubMed ID: 23879864
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability, and quality of life evaluation in six patients affected by Gorlin-Goltz syndrome and treated with vismodegib 150 mg/die: a retrospective monocentric cohort analysis.
    Scotti B; Melotti B; Baraldi C; Venturi F; Lambertini M; Dika E
    Ital J Dermatol Venerol; 2024 Aug; 159(4):453-454. PubMed ID: 39069844
    [No Abstract]   [Full Text] [Related]  

  • 11. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
    Chang AL; Atwood SX; Tartar DM; Oro AE
    JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
    Ally MS; Wysong A; Tang JY; Aasi S
    Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversible cutaneous side effects of vismodegib treatment.
    Kwong B; Danial C; Liu A; Chun KA; Chang AL
    Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
    [No Abstract]   [Full Text] [Related]  

  • 14. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 15. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 16. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 17. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma.
    Gibson M; Murrell DF
    Australas J Dermatol; 2020 May; 61(2):176-177. PubMed ID: 31747714
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of trichodysplasia spinulosa: case report of a patient with Gorlin syndrome treated with vismodegib.
    Richey JD; Graham TA; Katona T; Travers JB
    JAMA Dermatol; 2014 Sep; 150(9):1016-8. PubMed ID: 25054782
    [No Abstract]   [Full Text] [Related]  

  • 20. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.